Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892792 | 0.87 | ALDH1A1 (0.62) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL9892051 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL13284776 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL9892049 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL20458159 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL2123122 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL9892142 | 0.77 | ALDH1A1 (0.58) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL9107659 | 0.77 | MAPT (0.52) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL13257045 | 0.76 | ALDH1A1 (0.58) | ALDH1A1MAPTHSD17B10HPGDTSHR | |
| SCHEMBL9892288 | 0.72 | ALDH1A1 (0.57) | ALDH1A1MAPTHSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 3279/4885MAPT 4057/4885HSD17B10 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.